A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab
JEADV Clinical Practice · 2026-06 · 5 (2) · 644-647
DOI: 10.1002/jvc2.70221 ↗Kurz gefasst
Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 29.10.2025. Verfasst von Evangelos Christou und 2 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid‐refractory PL‐like eruptions, and may allow for continuation of ICI treatment.
Zitieren
APA
Christou, E., Edwards, S., & Affleck, A. (2026). A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab. JEADV Clinical Practice, 5(2), 644-647. https://doi.org/10.1002/jvc2.70221
Vancouver
Christou E, Edwards S, Affleck A. A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab. JEADV Clinical Practice. 2026;5(2):644-647. doi:10.1002/jvc2.70221
BibTeX
@article{Christou2026,
author = {Christou, Evangelos and Edwards, Sharon and Affleck, Andrew},
title = {A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab},
journal = {JEADV Clinical Practice},
year = {2026},
volume = {5},
number = {2},
pages = {644--647},
doi = {10.1002/jvc2.70221}
}
EUVIMED